Is Editas Medicine Going to $0? [Yahoo! Finance]
Editas Medicine, Inc. (EDIT)
Last editas medicine, inc. earnings: 2/26 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.editasmedicine.com
Company Research
Source: Yahoo! Finance
When looking only at the past 12 months, Editas Medicine (NASDAQ: EDIT) , a small-cap biotech company, seems to be doing well. The drugmaker's shares have soared by 80% over this period. However, zooming out gives a different picture: Editas Medicine has lost more than 90% of its market value in the past five years. Is the company's recent run sustainable, or will the stock -- whose price is just under $3 -- continue to fall until investors are left with worthless shares? Image source: Getty Images. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » A terrible track record Editas Medicine is a clinical-stage biotech . Pre-commercial drugmakers carry higher-than-average risk, as they routinely encounter significant clinical or regulatory roadblocks that sink their stock prices. Further, Editas Medicine speciali
Show less
Read more
Impact Snapshot
Event Time:
EDIT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EDIT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EDIT alerts
High impacting Editas Medicine, Inc. news events
Weekly update
A roundup of the hottest topics
EDIT
News
- Editas Medicine Details In Vivo CRISPR Plan, Targets Year-End Human Proof-of-Concept for EDIT-401 [Yahoo! Finance]Yahoo! Finance
- Editas Medicine, Inc. (EDIT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Editas Medicine (EDIT) was upgraded by JonesTrading from "hold" to "buy". They now have a $8.00 price target on the stock.MarketBeat
- Editas Medicine (EDIT) was given a new $6.00 price target by Robert W. Baird.MarketBeat
- Editas Medicine (EDIT) had its "buy" rating reaffirmed by Chardan Capital. They now have a $3.50 price target on the stock.MarketBeat
EDIT
Earnings
- 3/9/26 - Beat
EDIT
Sec Filings
- 3/16/26 - Form 4
- 3/16/26 - Form 4
- 3/16/26 - Form 4
- EDIT's page on the SEC website